In Iacoangeli et al. (1), five independent groups report that results published by Zalfa et al. (2) are not reproducible. Bagni now suggests (3) that different reagents, antibodies, or procedures might explain this lack of reproducibility. Iacoangeli et al. replicated the experimental conditions reported by Zalfa et al. whenever possible, as indicated. In several cases, however, reagents used by Zalfa et al. were not available. For instance, Zalfa et al. generated antibody rAM1 and used it to probe BC1–FMRP interactions in supershift and other assays. The antibody did not produce a supershift in brain extracts—as one would have expected if BC1 RNA did in fact bind to FMRP in vivo—but abolished the regular mobility shift (2). Despite repeated requests by several of the undersigned, antibody rAM1 was not provided. We urge the Bagni group (2) to make antibody rAM1 available for independent examination. In contrast, Iacoangeli et al. used two established anti-FMRP antibodies that have been independently validated and are publicly available. Bagni suggests that two other groups (4, 5) have published data in support of her claims. Both articles were quoted and discussed by Iacoangeli et al. (1). One of the undersigned (E.W.K.) coauthored one of these articles (4) and has confirmed that, although BC1 RNA does bind to FMRP in vitro, this binding is entirely nonspecific because it is completely abrogated by competitor tRNA (1). Bagni does not mention that Gabus et al. (4) reported a Kd of FMRP for tRNA of 25 nM, the same as for BC1 RNA. The second article (5) reported a weak BC1 RT-PCR signal in FMRP cross-linked immunoprecipitates and a stronger signal in MAP2 cross-linked immunoprecipitates. However, considering that MAP2 is not a known RNA binding protein, mere copurification cannot be taken as evidence for physical association (1). Thus, there is no confirmation, independent of the Bagni group, of a specific physical link between FMRP and BC1 RNA, as posited by Zalfa et al. (2). Similarly, the Zalfa et al. claim that FMRP is not associated with polyribosomes in neurons could not be confirmed in subsequent work (6, 7).
Footnotes
The authors declare no conflict of interest.
References
- 1.Iacoangeli A, et al. On BC1 RNA and the fragile X mental retardation protein. Proc Natl Acad Sci USA. 2008;105:734–739. doi: 10.1073/pnas.0710991105. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Zalfa F, et al. The fragile X syndrome protein FMRP associates with BC1 RNA and regulates the translation of specific mRNAs at synapses. Cell. 2003;112:317–327. doi: 10.1016/s0092-8674(03)00079-5. [DOI] [PubMed] [Google Scholar]
- 3.Bagni C. On BC1 RNA and the fragile X mental retardation protein. Proc Natl Acad Sci USA. 2008;105:E19. doi: 10.1073/pnas.0801034105. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.Gabus C, Mazroui R, Tremblay S, Khandjian EW, Darlix JL. The fragile X mental retardation protein has nucleic acid chaperone properties. Nucleic Acids Res. 2004;32:2129–2137. doi: 10.1093/nar/gkh535. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Johnson EM, et al. Role of Purα in targeting mRNA to sites of translation in hippocampal neuronal dendrites. J Neurosci Res. 2006;83:929–943. doi: 10.1002/jnr.20806. [DOI] [PubMed] [Google Scholar]
- 6.Stefani G, Fraser CE, Darnell JC, Darnell RB. Fragile X mental retardation protein is associated with translating polyribosomes in neuronal cells. J Neurosci. 2004;24:7272–7276. doi: 10.1523/JNEUROSCI.2306-04.2004. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.Khandjian EW, et al. Biochemical evidence for the association of fragile X mental retardation protein with brain polyribosomal ribonucleoparticles. Proc Natl Acad Sci USA. 2004;101:13357–13362. doi: 10.1073/pnas.0405398101. [DOI] [PMC free article] [PubMed] [Google Scholar]